Skip to main content

Phase 1

8
Pipeline Programs
5
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
3
PF-04965842Phase 11 trial
PF-05212372Phase 11 trial
UK-396,082Phase 11 trial
Active Trials
NCT03647670Completed25Est. Oct 2018
NCT01415102Completed24Est. Dec 2010
NCT01091532Completed48Est. Jul 2010
Calliditas Therapeutics
Calliditas TherapeuticsSweden - Stockholm
2 programs
2
GKT137831Phase 11 trial
SetanaxibPhase 11 trial
Active Trials
NCT03740217Completed15Est. Feb 2019
NCT04327089Completed64Est. Mar 2021
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AdalimumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03983876Completed207Est. Dec 2019
Saniona
SanionaDenmark - Glostrup
1 program
1
Metoprolol Succinate 25 MGPhase 11 trial
Active Trials
NCT03488719Completed37Est. Jun 2019
Handok
HandokKorea - Seoul
1 program
1
NOV1601Phase 11 trial
Active Trials
NCT04014257Completed17Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Calliditas TherapeuticsSetanaxib
HandokNOV1601
AlvotechAdalimumab
Calliditas TherapeuticsGKT137831
SanionaMetoprolol Succinate 25 MG
PfizerPF-04965842
PfizerPF-05212372
PfizerUK-396,082

Clinical Trials (8)

Total enrollment: 437 patients across 8 trials

NCT04327089Calliditas TherapeuticsSetanaxib

Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

Start: Jun 2020Est. completion: Mar 202164 patients
Phase 1Completed
NCT04014257HandokNOV1601

A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Start: Aug 2019Est. completion: Jan 202117 patients
Phase 1Completed
NCT03983876AlvotechAdalimumab

PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Start: Jul 2019Est. completion: Dec 2019207 patients
Phase 1Completed
NCT03740217Calliditas TherapeuticsGKT137831

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Start: Dec 2018Est. completion: Feb 201915 patients
Phase 1Completed
NCT03488719SanionaMetoprolol Succinate 25 MG

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Start: Jul 2018Est. completion: Jun 201937 patients
Phase 1Completed
NCT03647670PfizerPF-04965842

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Start: Jul 2018Est. completion: Oct 201825 patients
Phase 1Completed
NCT01415102PfizerPF-05212372

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

Start: Sep 2010Est. completion: Dec 201024 patients
Phase 1Completed
NCT01091532PfizerUK-396,082

A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.

Start: Mar 2010Est. completion: Jul 201048 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.